Novo Nordisk’s diabetes drug Victoza shows cardiovascular risk benefits

Novo Nordisk has announced new clinical trial data that further underline the cardiovascular risk benefits offered by its type 2 diabetes therapy Victoza.

A post-hoc analysis of the LEADER cardiovascular outcomes trial has indicated that treatment with Victoza delivered similar reductions in the occurrence of major cardiovascular events in patients at high risk, regardless of whether or not they experienced an episode of severe hypoglycaemia during the trial.

Regardless of treatment group, people who experienced a severe hypoglycaemic episode were shown to be at a significantly greater risk of major cardiovascular adverse events or death, particularly within 60 days of the hypoglycaemic episode occurring.

It was also shown that people treated with Victoza experienced significantly fewer episodes of severe hypoglycaemia when compared to placebo.

Steven Marso, medical director for cardiovascular services at HCA Midwest Health Heart and Vascular Institute in Kansas, said: "While the lower incidence of severe hypoglycaemia with Victoza could contribute to the observed beneficial effect on major cardiovascular events in LEADER, this new analysis indicates that the results cannot be explained by these differences in hypoglycaemia."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.